(Total Views: 806)
Posted On: 02/07/2017 11:53:34 AM
Post# of 108
$PVCT & Pfizer, Inc.
Discussions between researchers at Provectus and Pfizer led to jointly owned US patent 9,107,887 covering the use of Provectus' investigational anti-cancer drug, PV-10, in combination with systemic inhibitors of immune system down-regulation, such as anti-CTLA-4, PD-1 and PD-L1 antibodies, along with enhancers of immune system up-regulation, such as IL-2 and interferon-gamma.
Discussions between researchers at Provectus and Pfizer led to jointly owned US patent 9,107,887 covering the use of Provectus' investigational anti-cancer drug, PV-10, in combination with systemic inhibitors of immune system down-regulation, such as anti-CTLA-4, PD-1 and PD-L1 antibodies, along with enhancers of immune system up-regulation, such as IL-2 and interferon-gamma.
(0)
(0)
Here We Go!!!!
